Comparative Pharmacology
Head-to-head clinical analysis: HIPPURAN I 131 versus MPI KRYPTON 81M GENERATOR.
Head-to-head clinical analysis: HIPPURAN I 131 versus MPI KRYPTON 81M GENERATOR.
HIPPURAN I 131 vs MPI KRYPTON 81M GENERATOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIPPURAN I 131 (iodohippurate sodium I-131) is a radiopharmaceutical that is actively transported by the renal tubules, allowing dynamic imaging of renal function. The I-131 isotope emits beta and gamma radiation, enabling scintigraphic visualization of renal perfusion and excretion.
Krypton-81m (81mKr) is a short-lived radionuclide that decays by isomeric transition emitting gamma rays (190 keV). When inhaled, it distributes in the lungs according to regional ventilation. Imaging is performed using a gamma camera to assess pulmonary ventilation. The generator produces 81mKr from its parent rubidium-81 (81Rb).
1 mCi (37 MBq) intravenously for adults; dose adjusted based on clinical indication and imaging protocol.
Intravenous infusion of krypton-81m gas in oxygen, typically 400-800 MBq (10-20 mCi) per study, administered via generator elution with a flow rate of 500-1000 mL/min. Adult dose per lung ventilation study: 100-400 MBq (2.7-10.8 mCi) inhaled in a single breath or continuous breathing for 1-2 minutes.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged in renal impairment, up to 20-40 hours in severe impairment.
Physical half-life of krypton-81m: 13.1 seconds; biological half-life is negligible as it is inert gas eliminated via exhalation.
Renal: >95% excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Renal: ~100% (krypton-81m is exhaled and decay products are excreted renally; as a gas, the primary elimination is via exhalation, with the decay product rubidium-81 cleared renally).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical